CA3117134A1 - Cellules nk ciml et procedes associes - Google Patents
Cellules nk ciml et procedes associes Download PDFInfo
- Publication number
- CA3117134A1 CA3117134A1 CA3117134A CA3117134A CA3117134A1 CA 3117134 A1 CA3117134 A1 CA 3117134A1 CA 3117134 A CA3117134 A CA 3117134A CA 3117134 A CA3117134 A CA 3117134A CA 3117134 A1 CA3117134 A1 CA 3117134A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- ciml
- cell
- expanded
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 245
- 238000000034 method Methods 0.000 title claims description 74
- 102000004127 Cytokines Human genes 0.000 claims abstract description 82
- 108090000695 Cytokines Proteins 0.000 claims abstract description 82
- 231100000135 cytotoxicity Toxicity 0.000 claims abstract description 51
- 230000003013 cytotoxicity Effects 0.000 claims abstract description 51
- 210000004700 fetal blood Anatomy 0.000 claims abstract description 39
- 210000005087 mononuclear cell Anatomy 0.000 claims abstract description 35
- 239000011886 peripheral blood Substances 0.000 claims abstract description 23
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 23
- 210000004027 cell Anatomy 0.000 claims description 136
- 239000000203 mixture Substances 0.000 claims description 82
- 108010057840 ALT-803 Proteins 0.000 claims description 69
- 102000003810 Interleukin-18 Human genes 0.000 claims description 62
- 108090000171 Interleukin-18 Proteins 0.000 claims description 62
- 102000003812 Interleukin-15 Human genes 0.000 claims description 40
- 108090000172 Interleukin-15 Proteins 0.000 claims description 40
- 230000004936 stimulating effect Effects 0.000 claims description 40
- 108020001507 fusion proteins Proteins 0.000 claims description 35
- 102000037865 fusion proteins Human genes 0.000 claims description 35
- 230000014509 gene expression Effects 0.000 claims description 35
- 108010065805 Interleukin-12 Proteins 0.000 claims description 30
- 102000013462 Interleukin-12 Human genes 0.000 claims description 30
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 15
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 14
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 14
- 239000013060 biological fluid Substances 0.000 claims description 14
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 13
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 13
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 13
- 230000003247 decreasing effect Effects 0.000 claims description 13
- 230000003213 activating effect Effects 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 102100038077 CD226 antigen Human genes 0.000 claims description 10
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims description 10
- 230000002147 killing effect Effects 0.000 claims description 10
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 9
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000012636 effector Substances 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 102000000588 Interleukin-2 Human genes 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 239000002609 medium Substances 0.000 description 22
- 230000004913 activation Effects 0.000 description 20
- 230000000638 stimulation Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 8
- 108091008042 inhibitory receptors Proteins 0.000 description 8
- 238000002784 cytotoxicity assay Methods 0.000 description 7
- 231100000263 cytotoxicity test Toxicity 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 108010002586 Interleukin-7 Proteins 0.000 description 6
- 102000000704 Interleukin-7 Human genes 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000012737 fresh medium Substances 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 102000015696 Interleukins Human genes 0.000 description 5
- 108010063738 Interleukins Proteins 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 108010074108 interleukin-21 Proteins 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000011109 contamination Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 4
- 210000000581 natural killer T-cell Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 3
- 102100030703 Interleukin-22 Human genes 0.000 description 3
- 230000006051 NK cell activation Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 2
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000002698 KIR Receptors Human genes 0.000 description 2
- 108010043610 KIR Receptors Proteins 0.000 description 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 2
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 2
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000001808 exosome Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 1
- 102100021186 Granulysin Human genes 0.000 description 1
- 101710168479 Granulysin Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 101150069255 KLRC1 gene Proteins 0.000 description 1
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 1
- 101100261153 Mus musculus Mpl gene Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 229940127143 NHS-IL12 immunocytokine Drugs 0.000 description 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000030941 detection of cell density Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000012526 feed medium Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003566 hemangioblast Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 102000053350 human FCGR3B Human genes 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 102220311640 rs1382779104 Human genes 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- -1 stem cell factors Proteins 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002483 superagonistic effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2312—Interleukin-12 (IL-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2318—Interleukin-18 (IL-18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Abstract
L'invention concerne des cellules NK à mémoire induite par les cytokines (CIML) présentant une cytotoxicité améliorée. Idéalement, les cellules NK CIML sont dérivées d'une fraction de cellules mononucléaires du sang périphérique ou du sang du cordon ombilical. Dans d'autres aspects envisagés, les cellules NK CIML sont multipliées et induites dans un environnement de production autonome et contenu qui réduit sensiblement la complexité de fonctionnement et le coût de production.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/040889 WO2021006876A1 (fr) | 2019-07-08 | 2019-07-08 | Cellules nk ciml et procédés associés |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3117134A1 true CA3117134A1 (fr) | 2021-01-14 |
Family
ID=74114922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3117134A Abandoned CA3117134A1 (fr) | 2019-07-08 | 2019-07-08 | Cellules nk ciml et procedes associes |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3853353A4 (fr) |
| JP (1) | JP2022540267A (fr) |
| KR (1) | KR20210079381A (fr) |
| CN (1) | CN113195706A (fr) |
| AU (1) | AU2019456438A1 (fr) |
| CA (1) | CA3117134A1 (fr) |
| IL (1) | IL283997A (fr) |
| SG (1) | SG11202104256XA (fr) |
| WO (1) | WO2021006876A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3211456A1 (fr) * | 2021-03-03 | 2022-09-09 | Immunitybio, Inc. | Cellules m-cenk hautement puissantes et procedes |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4275680B2 (ja) * | 2006-04-28 | 2009-06-10 | 裕 照沼 | リンパ球の活性・増殖に係る培養方法 |
| ES2899890T3 (es) * | 2014-06-30 | 2022-03-15 | Altor Bioscience Corp | Moléculas basadas en IL-15 y métodos de uso de las mismas |
| CN105219713A (zh) * | 2015-11-20 | 2016-01-06 | 崔长友 | 用于肿瘤过继性免疫的高增殖力、高杀伤力nk细胞 |
| US10300089B2 (en) * | 2016-11-08 | 2019-05-28 | University Of Central Florida Research Foundation, Inc. | Methods for high scale therapeutic production of memory NK cells |
| MX2019010172A (es) * | 2017-02-28 | 2019-12-18 | Affimed Gmbh | Combinacion de un anticuerpo anti-cd16a con una citocina. |
| AU2018231170B2 (en) * | 2017-03-06 | 2020-07-16 | Altor Bioscience Corporation | IL-15-based fusions to IL-12 and IL-18 |
-
2019
- 2019-07-08 CN CN201980082326.4A patent/CN113195706A/zh active Pending
- 2019-07-08 JP JP2021534175A patent/JP2022540267A/ja not_active Withdrawn
- 2019-07-08 AU AU2019456438A patent/AU2019456438A1/en not_active Abandoned
- 2019-07-08 WO PCT/US2019/040889 patent/WO2021006876A1/fr unknown
- 2019-07-08 EP EP19936806.9A patent/EP3853353A4/fr not_active Withdrawn
- 2019-07-08 CA CA3117134A patent/CA3117134A1/fr not_active Abandoned
- 2019-07-08 KR KR1020217018219A patent/KR20210079381A/ko not_active Application Discontinuation
- 2019-07-08 SG SG11202104256XA patent/SG11202104256XA/en unknown
-
2021
- 2021-06-14 IL IL283997A patent/IL283997A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113195706A (zh) | 2021-07-30 |
| KR20210079381A (ko) | 2021-06-29 |
| IL283997A (en) | 2021-07-29 |
| EP3853353A4 (fr) | 2022-05-18 |
| SG11202104256XA (en) | 2021-05-28 |
| AU2019456438A1 (en) | 2021-05-20 |
| JP2022540267A (ja) | 2022-09-15 |
| WO2021006876A1 (fr) | 2021-01-14 |
| EP3853353A1 (fr) | 2021-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Granzin et al. | Shaping of natural killer cell antitumor activity by ex vivo cultivation | |
| TWI612137B (zh) | 含免疫細胞之組成物的製造方法及癌症治療用組成物 | |
| KR20170084337A (ko) | 감마델타 t 세포 증식 절차 | |
| JP6073417B2 (ja) | 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物 | |
| US20220333078A1 (en) | Method for ex vivo expansion CD34+HSPCs into NK cells using an aryl hydrocarbon receptor antagonist | |
| US20210361711A1 (en) | CIML NK cells and Methods Therefor | |
| Shimasaki et al. | Engineering of natural killer cells for clinical application | |
| WO2022228539A1 (fr) | Procédé de préparation de cellules car-cik ayant une proportion élevée de cellules nkt, et son application | |
| CA3117134A1 (fr) | Cellules nk ciml et procedes associes | |
| US20210009954A1 (en) | Mononuclear Cell Derived NK Cells | |
| ES2336302T3 (es) | Produccion de celulas ttcr gamma delta. | |
| JP2002528115A (ja) | ＴｃＲγδＴ細胞の生産方法 | |
| JP7213976B2 (ja) | 単核細胞由来のｎｋ細胞 | |
| AU2001248162A1 (en) | Production of TcR gamma delta T cells | |
| US20210087530A1 (en) | Compositions and methods for culturing and expanding cells | |
| US20240117309A1 (en) | Methods for expanding t cell populations | |
| US20030157060A1 (en) | Production of tcr gamma delta t cells | |
| Kim | Cultivation of Natural Killer Cell for Immunotherapy | |
| JP2024508906A (ja) | 極めて強力なｍ－ｃｅｎｋ細胞及び方法 | |
| Kohgo et al. | Generation of lymphokine activated killer cells in a new high density dialyzing culture apparatus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210420 |
|
| EEER | Examination request |
Effective date: 20210420 |
|
| EEER | Examination request |
Effective date: 20210420 |
|
| FZDE | Discontinued |
Effective date: 20230802 |